Kyverna (KYTX) CEO receives 350,000 options and 58,000 RSUs in equity grants

Rhea-AI Filing Summary

Kyverna Therapeutics’ Chief Executive Officer Biddle Warner Weston received new equity awards as part of his compensation. He was granted stock options for 350,000 shares of common stock at an exercise price of $8.95 per share, expiring on March 13, 2036. One quarter of these options vest on March 13, 2027, with the remaining shares vesting in equal monthly installments of 1/48 each month thereafter, contingent on his continuous service.

He also received a restricted stock unit award covering 58,000 shares of common stock. One quarter of this RSU grant vests on March 13, 2027, and an additional one quarter vests on each one-year anniversary after that date, also subject to continued service. Following these awards, his reported holdings include 58,000 shares of common stock and 350,000 options, reflecting compensation-related acquisitions rather than open-market purchases.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Biddle Warner Weston

(Last) (First) (Middle)

C/O KYVERNA THERAPEUTICS, INC.

5980 HORTON ST., STE 550

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kyverna Therapeutics, Inc. [ KYTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		A		58,000(1)	A	$0	58,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.95	03/13/2026		A		350,000		(2)	03/13/2036	Common Stock	350,000	$0	350,000	D

Explanation of Responses:

1. Represents a restricted stock unit award of common stock and 1/4th of the shares underlying the restricted stock unit award shall vest on March 13, 2027 and an additional 1/4th of the shares underlying the restricted stock unit award shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

2. 1/4th of the shares subject to the option shall vest on March 13, 2027 and an additional 1/48th of the shares subject to the option shall vest on the same day of each month thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Remarks:

Exhibit 24 - Power of Attorney

	By: /s/ Marc Grasso, as Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Kyverna (KYTX) report for its CEO on this Form 4?

The filing shows CEO Biddle Warner Weston received compensation-related equity awards: 350,000 stock options and 58,000 restricted stock units. These are grants at no purchase price, not open-market buying or selling of Kyverna Therapeutics common stock.

How many stock options did the Kyverna (KYTX) CEO receive and at what exercise price?

Biddle Warner Weston was granted stock options covering 350,000 shares of Kyverna common stock at an exercise price of $8.95 per share. The options expire on March 13, 2036 and vest over time, contingent on his continued service with the company.

What is the vesting schedule for the Kyverna (KYTX) CEO’s new stock options?

One quarter of the 350,000 options vest on March 13, 2027. The remaining three quarters vest in equal monthly installments of 1/48 of the total grant each month thereafter, subject to Biddle Warner Weston’s continuous service to Kyverna Therapeutics.

What restricted stock units did Kyverna (KYTX) grant to its CEO and how do they vest?

Kyverna granted Biddle Warner Weston 58,000 restricted stock units tied to common stock. One quarter vests on March 13, 2027, with an additional one quarter vesting on each one-year anniversary after that date, assuming he remains in continuous service with the company.

Are the Kyverna (KYTX) CEO’s Form 4 transactions open-market purchases or sales?

The transactions are equity grants, not open-market trades. The Form 4 reports awards of stock options and restricted stock units to Biddle Warner Weston as compensation, all at a transaction price of $0.00 per share, rather than discretionary buying or selling.

What are Biddle Warner Weston’s reported Kyverna (KYTX) holdings after these grants?

After the reported transactions, Biddle Warner Weston holds 58,000 shares of Kyverna common stock and 350,000 stock options. These positions reflect his compensation awards and will vest over several years, subject to his continued service with the company.